Envestnet Portfolio Solutions Inc. Has $19.30 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Envestnet Portfolio Solutions Inc. increased its position in shares of Danaher Co. (NYSE:DHR) by 11.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 84,054 shares of the conglomerate’s stock after buying an additional 8,956 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Danaher were worth $19,295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. FMR LLC boosted its holdings in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. Raymond James Financial Inc. acquired a new stake in Danaher during the fourth quarter worth about $391,172,000. Van ECK Associates Corp increased its stake in Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after acquiring an additional 916,513 shares during the period. Parnassus Investments LLC raised its holdings in Danaher by 31.8% in the 4th quarter. Parnassus Investments LLC now owns 3,105,388 shares of the conglomerate’s stock valued at $712,842,000 after acquiring an additional 749,136 shares in the last quarter. Finally, Proficio Capital Partners LLC grew its holdings in shares of Danaher by 29,287.7% during the 4th quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock worth $135,189,000 after purchasing an additional 586,925 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is currently owned by insiders.

Danaher Stock Up 3.4 %

NYSE:DHR opened at $211.09 on Monday. The stock’s fifty day moving average price is $220.07 and its two-hundred day moving average price is $240.45. The company has a market cap of $150.87 billion, a price-to-earnings ratio of 39.98, a P/E/G ratio of 2.66 and a beta of 0.82. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm earned $2.09 EPS. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.61%. Danaher’s payout ratio is currently 24.24%.

Analyst Ratings Changes

DHR has been the subject of a number of analyst reports. Jefferies Financial Group reduced their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Wells Fargo & Company decreased their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Stifel Nicolaus raised Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price for the company in a report on Friday. Guggenheim initiated coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Finally, Raymond James reiterated a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $277.76.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.